Thanks Normand and West CoastI think the investment outlook here can be summed up easily...We have a product that appears to improve outcomes for many types of cancers when combined with a variety of immunotherapies. Problem is it will take considerable time and resources to complete Phase 3 trials...and we may just burn through our cash before we can get there. One would think the recent study results would spark partnership interest...but maybe those in the know don't think we are far enough along. Sure it might get more expensive to jump in later with a buyout offer or partnership agreement...but it probably makes sense to wait....my idiot football team signed Todd Gurley, Brandon Cooks and Jared Goff to what they thought would be cost effective long term contracts----got burned in all three cases----guessing flakey biotech business has similar risks...better to pay up for a sure thing.....